Studies demonstrating poor prognostic impact of MYC and BCL2 expression in DLBCL at diagnosis
| Reference . | Number of patients . | Therapy . | COO assignment . | % MYC/BCL2 thresholds . | % DE-DLBCL . | % DE-DLBCL . | % HGBL-DH . | % HGBL-DH that are GCB . | |
|---|---|---|---|---|---|---|---|---|---|
| ABC . | GCB . | ||||||||
| 11 | 193 | R-CHOP | Hans | 40/70 | 29 | 18 | 11 | 6 | 91 |
| 10 | 307 | R-CHOP | GEP/Choi | 40/50 | 21 | 16 | 5 | 5 | 64 |
| 12 | 466 | R-CHOP | GEP | 40/70 | 34 | 22 | 12 | 2.3 | 90 |
| 13 | 336 | R-CHOP | Hans | 40/70 | 28 | 23 | 4 | 1 | NA |
| 14 | 506 | R-CHOP | Hans | 40/>0 | 35 | NA | NA | 5 | NA |
| 15 | 311 | R-CHOP | Choi | 50/30 | 44 | 16 | 28 | NA | NA |
| 8 | 898 | R-CHOP | GEP/Choi | 70/70 | 18 | 21 | 14 | 3 | 95 |
| 68 | 40 | Dose-intensified R-CHOP + ASCT | Hans | 40/50 | 25 | 18 | 7 | 5 | |
| Reference . | Number of patients . | Therapy . | COO assignment . | % MYC/BCL2 thresholds . | % DE-DLBCL . | % DE-DLBCL . | % HGBL-DH . | % HGBL-DH that are GCB . | |
|---|---|---|---|---|---|---|---|---|---|
| ABC . | GCB . | ||||||||
| 11 | 193 | R-CHOP | Hans | 40/70 | 29 | 18 | 11 | 6 | 91 |
| 10 | 307 | R-CHOP | GEP/Choi | 40/50 | 21 | 16 | 5 | 5 | 64 |
| 12 | 466 | R-CHOP | GEP | 40/70 | 34 | 22 | 12 | 2.3 | 90 |
| 13 | 336 | R-CHOP | Hans | 40/70 | 28 | 23 | 4 | 1 | NA |
| 14 | 506 | R-CHOP | Hans | 40/>0 | 35 | NA | NA | 5 | NA |
| 15 | 311 | R-CHOP | Choi | 50/30 | 44 | 16 | 28 | NA | NA |
| 8 | 898 | R-CHOP | GEP/Choi | 70/70 | 18 | 21 | 14 | 3 | 95 |
| 68 | 40 | Dose-intensified R-CHOP + ASCT | Hans | 40/50 | 25 | 18 | 7 | 5 | |
This table summarizes the key studies that have identified the coexpression of MYC and BCL2 as a poor prognostic factor in patients with DLBCL. Cell of origin (COO) assignment was performed by gene expression profiling (GEP) or by using immunohistochemistry algorithms, the most common being Hans.113-115 The average proportion of DE-DLBCL in all DLBCL is ∼30%, with two-thirds of patients being the ABC subtype and one-third being the GCB subtype. HGBL-DH occurs in ∼5% of DLBCLs, and >90% of patients are assigned as GCB in all but 1 study.